Madrigal Pharmaceuticals, Inc.
MDGL
$531.77
-$8.12-1.50%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
9/13/2025
-
MarketBeat
5/13/2026
-
TipRanks Financial Blog
5/12/2026
-
MarketBeat
5/12/2026
-
Tickeron - Stocks
5/11/2026
-
MarketBeat
5/11/2026
-
Simply Wall St
5/9/2026
-
Simply Wall St
5/7/2026
-
Globe Newswire
5/7/2026
-
Zacks Investment Research
5/7/2026
-
Zacks Investment Research
5/7/2026
-
TipRanks Financial Blog
5/7/2026
-
TipRanks Financial Blog
5/7/2026
-
Simply Wall St
5/7/2026
-
TipRanks Financial Blog
5/7/2026
-
The Cerbat Gem
5/7/2026
-
MarketBeat
5/6/2026
-
TipRanks Financial Blog
5/6/2026
-
The Cerbat Gem
5/6/2026
-
MarketBeat
5/6/2026
-
Seeking Alpha: Transcripts
5/6/2026
-
Yahoo! Finance: News
5/6/2026
-
Benzinga
5/6/2026
-
MarketBeat
5/6/2026
-
Zacks Investment Research
9/10/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 6, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 3 and 7 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
267 824 2827
Address
Four Tower Bridge
200 Barr Harbor Drive - Suite 200
West Conshohocken, PA 19428
200 Barr Harbor Drive - Suite 200
West Conshohocken, PA 19428
Country
Year Founded
Business Description
Sector
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers...
more